|
Life Science in the Capital Market - Biosimilars
Members of the DVFA Life Science Commission
Published in November 2010
- Origins and Future of the Biosimilars Industry, Dr. Ralf Emmerich, Capgemini Deutschland GmbH
- Regulatory Requirements and Challenges for Biosimilars in Europe, Prof. Dr. Marietta Kaszkin-Bettag, PharmaLex GmbH
- Biosimilars - Legal, IP and Transactional Aspects, Dr. iur. Dr. med. Adem Koyuncu, Mayer Brown LLP
- Biosimilars - Risks and Opportunities from a Pharmaceutical Perspective, Prof. Dr. Theodor Dingermann, Institute of Pharmaceutical Biology, Biocenter Frankfurt
- Cost Savings Potential of Biosimilars in the German Health Care System, Prof. Dr. Bertram Häussler, IGES Institute GmbH
- The Long View: Biosimilars - Henry Ford on Antibody Manufacturing, Ronny Gal, Sanford C. Bernstein & Co.
- Biosimilars - Commercialisation Approaches for Europe, Paul Greenland, Hospira UK Limited
- The Biosimilar Opportunity in Asia, Motoya Kohtani and Karan Ahuja, Nomura Securities Co., Ltd.
- Important Lessons from the Implementation of the European Biosimilar Pathway, Charles Brigden, Amgen UK & Ireland
- Biosimilars in an Individualized Therapeutics World - The Challenge in Oncology, Dr. Rainer Wessel and Dr. Karl-Heinz Sellinger, Ganymed Pharmaceuticals AG und SellWiss GmbH
- Valuation of Biosimilar Products and Pipelines, Dr. Elmar Kraus, DZ BANK AG
- Biosimilars in the Capital Market, Dr. med. Markus Manns, Union Investment Privatfonds GmbH
- Glossary
- Bibliography
- DVFA Life Science Commission
Download:
Life Science in the Capital Market - Biosimilars [PDF; 1.911 KB]
Order Form:
Buy Hardcopy |
|